Investors are constantly in search of factors that can influence price fluctuations in financial markets. A significant catalyst known to have a substantial impact on stock prices is news. Favorable news releases can occasionally propel stocks to remarkable highs.
Now, let’s look at a few stocks that could be poised to benefit from their recent announcements
In a significant release on August 31, 2023, Epazz Inc. (OTC: EPAZ) announced the showcasing of its cutting-edge ZenaDrone 1000 to multiple government security agencies in the United States. This momentous presentation served as a testament to Epazz’s status as a mission-critical provider of drone technologies, blockchain mobile apps, and cloud-based business software solutions.
The successful presentation is a clear indication of Epazz’s dedication to innovation and collaboration. The management is actively working to onboard these government security agencies as pilot customers, providing them with full access to the ZenaDrone 1000 for a 90-day evaluation period.
One of the pivotal aspects of this release from EPAZ is its’ detailed nine-month roadmap, which provides insights into the company’s vision for the near future:
In the third quarter of 2023, Epazz plans to continue signing with military and government security agencies. They aim to increase the production of the ZenaDrone 1000, complete a joint venture in Brazil, and initiate the joint venture process in South Africa.
Moving into the fourth quarter of 2023, the company is set to deliver the ZenaDrone 1000 to Drone as a Service joint ventures and partners. The ZenaDrone 1000 will also be deployed in military projects and government security agencies for initial pilot programs. Epazz aims to secure a software acquisition before the end of the year, release upgraded versions of their cloud business software with artificial intelligence engines, and generate additional revenue from the Smart Glasses Project while attracting new customers.
The first quarter of 2024 holds exciting prospects, with plans to complete an audit for uplisting to OTCQB, release the ZenaDrone IQ Square for indoor drones, and initiate the prototype for the ZenaDrone 2000, a super heavy-lift hybrid drone.
Shaun Passley, Ph.D., CEO of Epazz Inc., said, “We are excited about the next nine months; our marketing efforts are working, and we are turning meetings into demos, and finally we are getting close to the next level.”
Epazz Inc. is not just about drones; it also demonstrates a commitment to advancing its software products with artificial intelligence engines. This forward-looking approach aims to assist customers in optimizing their organizations, showcasing the company’s dedication to technological advancement.
Epazz Inc.’s update on August 31, 2023, signals a significant leap forward. As it continues to execute its roadmap, the company has the potential to make significant contributions to various industries. Investors and technology enthusiasts may find this an enticing opportunity as EPAZ paves the way for innovation and collaboration in the dynamic world of technology.
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company, is on a mission to revolutionize the treatment of complex diseases using a novel approach involving endogenous metabolic modulators (EMMs). The company’s innovative model allows for the evaluation of its EMM compositions through clinical studies, and it recently received significant news that could propel its stock forward.
On August 29, 2023, the U.S. Patent and Trademark Office (USPTO) granted Axcella a valuable patent, U.S. Patent No. 11,737,999. This patent includes claims covering methods of use of Candidate AXA1125, designed to treat individuals suffering from post-acute sequelae of COVID-19 (PASC), commonly known as Long COVID, with a focus on fatigue.
AXA1125 is a unique composition of EMMs aimed at simultaneously supporting metabolic, inflammatory, and fibrotic pathways associated with fatigue. It’s worth noting that Axcella had previously been granted patents related to AXA1125, covering methods of use and compositions, with anticipated expiration dates in 2037. This new patent significantly extends their intellectual property protection, with an expiration date anticipated for 2042.
Paul F. Fehlner, J.D., Ph.D., Senior Vice President and Chief Legal Officer of Axcella, emphasized the importance of this patent, which adds to their global patent portfolio and strengthens their position regarding AXA1125. He emphasized that all these patents are fully owned by Axcella, underscoring their commitment to this innovative treatment.
Bill Hinshaw, President and Chief Executive Officer of Axcella, highlighted the significance of AXA1125 in treating long-term COVID Fatigue. He noted the continued advancement in understanding the disease and the importance of mitochondrial function. AXA1125, as a mitochondrial activator, holds the potential to address the challenges faced by millions of long-term COVID patients dealing with fatigue.
With this recent patent grant, Axcella Therapeutics has taken a significant step forward in its mission to provide hope and relief to long-term COVID patients. This development could serve as a catalyst for a rebound for AXLA as it positions itself at the forefront of innovative treatments for long-term COVID and related conditions. Investors and those closely following medical advancements might want to watch Axcella’s progress with interest.
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) is a company with a clear mission: to transform healthcare. Their approach is comprehensive, involving various strategies to reshape the industry.
Novo’s strategy centers on decentralizing healthcare, making it more accessible and cost-effective. They’re expanding their primary care services through various channels, including affiliate networks, franchise-operated clinics, and corporate-operated facilities. This multifaceted approach ensures that patients receive the care they need, where they need it.
To achieve this, Novo leverages advanced technology to connect patients with healthcare practitioners, extending healthcare services beyond traditional clinics and into patients’ homes. They’re also developing personalized health and wellness products, emphasizing prevention and maintenance care.
On September 1, 2023, Novo Integrated Sciences received an Underwriting Clearance Notice from RC Consulting Group LLC, marking a significant milestone for investors. This clearance paves the way for a transformative financial transaction—an unsecured 15-year $70,000,000 promissory note with a Buyer, providing debt funding of $57,000,000. The note carries a 1.52% yield (non-compounding) per annum and matures 15 years from the date of issuance. Importantly, this transaction involves no conversion of debt, issuance of shares, or grant of warrants by Novo to the Buyer.
Novo Integrated Sciences is all about taking tangible steps to reshape the healthcare industry through a multifaceted approach. For investors, keeping a close watch on Novo (NVOS) is a prudent move as the company continues to advance its comprehensive patient-focused platform, redefining healthcare for the better.
iQSTEL Inc. (OTC-QX: IQST), a multinational publicly listed company, is preparing for a Nasdaq up-listing with a projected FY2023 revenue forecast of $120 million. The company’s mission is to make essential tools accessible to people regardless of their background, recognizing that these tools are fundamental to meeting the human hierarchy of needs, such as physiological, safety, relationship, esteem, and self-actualization needs. iQSTEL operates through four core Business Divisions: Telecommunications, Fintech, Electric Vehicles, and Metaverse.
IQST recently announced the release of version 1.2 (v1.2) of its AI-Enhanced Metaverse application, marking its foray into the AI and Metaverse markets. The company reported over $93 million in annual revenue for 2022 and is on track to meet or exceed its $120 million FY-2023 revenue target. iQSTEL is diversifying its services to expand revenues and margins while delivering enhanced value to customers.
The iQSTEL AI-Enhanced Metaverse application v1.2 is available across various platforms, including desktop browsers, the App Store for iPhone and iPad, and Google Play for Android devices. The “iQSTEL Metaverse” application was created by Reality Border, a division of iQSTEL that specializes in AI-Enhanced Metaverse.
In v1.2, users can experience several enhancements, including a voice welcome and introduction, options to mute videos and non-player characters (NPC), accelerated user movements, multiple media screens, an Exhibition Room showcasing products like iQSTEL’s EV Motorcycle TuVolten 550 Elite with interactive NPC discussions, an auditorium for product reviews, and an enhanced Shopping Center with purchase options. Users can also download iQSTEL’s Fintech Services Global Money App through app download gateways.
Mr. Iglesias, CEO of IQSTEL, commented: “We are very proud of what we have achieved in a short time. We have started our commercial promotion, and we are already engaged in developing our first potential client opportunities for our Metaverse services with a Bank and a Retail Store. We are excited about the journey ahead and look forward to sharing our progress with you.
iQSTEL’s AI-Enhanced Metaverse Division, Reality Borders, aims to provide a comprehensive suite of media content, exhibition rooms, shopping centers, auditoriums, meeting rooms, entertainment, gaming, and customizable design options. This platform enables video calls, chat services, and interactions with celebrity influencers, enhancing customer interactions and experiences.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Epazz Inc. to assist in the production and distribution of content. ‘CGR’ is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Please visit CapitalGainsReport.com/Disclaimer for full disclaimer.